Co-Principal Investigators:
Wendy Kim, DO – Loyola University and Beth Drolet, MD – University of Wisconsin
Overview:
This was a multicenter retrospective review. A RedCap survey was designed to capture information regarding timolol and propranolol use in premature and young infants. Investigators aimed to determine whether side effects were more likely in this population and if so, which side effects were more common. Included were infants < 8 weeks corrected gestational age who were treated for infantile hemangioma with oral propranolol 0.5 mg/kg/ day or greater, as well as infants treated with transcutaneous timolol. Excluded were infants > 8 weeks corrected gestational age treated with beta blocker for infantile hemangioma. Data collected included gestational age, birth weight, sex, age at initiation of therapy, size of infantile hemangioma, type of infantile hemangioma, indication for treatment, dosing, comorbidities, screening workup, and side effects with grading.
Status:
Complete.